Effect of leukotriene receptor antagonist on cough variant asthma.
- Author:
Zhi-min HE
1
;
Yu-biao GUO
;
Can-mao XIE
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Asthma; complications; drug therapy; Case-Control Studies; Cough; complications; drug therapy; Female; Follow-Up Studies; Humans; Leukotriene Antagonists; adverse effects; pharmacology; therapeutic use; Male; Receptors, Leukotriene; metabolism; Recurrence
- From: Journal of Southern Medical University 2009;29(4):694-696
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the curative effect of leukotriene receptor antagonist on cough variant asthma (CVA).
METHODSSixty-four CVA patients received treatment with bricany and montelukas and 68 control patients had bricany treatment for 4 weeks. The recurrence rate was observed in the two groups during the follow-up for 6 months.
RESULTSThe remission time of two groups were 2.5-/+3.6 and 5.3-/+3.8 days in acute phase, respectively, showing a significant difference between them (P<0.05). The recurrence rate of the two groups within 6 months were 20.09% and 40.87%, respectively, showing also significantly differences (P<0.05).
CONCLUSIONLeukotriene receptor antagonist and bricany can effectively control CVA and significantly lower the short-term recurrence rate of CVA.
